Technical Analysis for KROS - Keros Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 53.96 | -0.53% | -0.29 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical KROS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -0.53% | |
| Golden Cross | Bullish | -0.53% | |
| Lizard Bullish | Bullish Day Trade Setup | -0.53% | |
| Doji - Bullish? | Reversal | -0.53% | |
| Lower Bollinger Band Touch | Weakness | -0.53% | |
| Oversold Stochastic | Weakness | -0.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| 20 DMA Resistance | about 23 hours ago |
| Up 1 ATR | about 23 hours ago |
| Up 5% | about 24 hours ago |
| Rose Above 10 DMA | about 24 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/08/2021
Keros Therapeutics, Inc. Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Hypertension Disorders Hematology Therapeutic Product Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Syndromes Osteoporosis Genodermatoses Molecule Product Myelodysplastic Syndromes Skeletal Disorders Myelofibrosis Bone Disease Thrombocytopenia Blood Disorders Hematopathology Musculoskeletal Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 86.8 |
| 52 Week Low | 28.5 |
| Average Volume | 158,456 |
| 200-Day Moving Average | 47.60 |
| 50-Day Moving Average | 47.86 |
| 20-Day Moving Average | 57.97 |
| 10-Day Moving Average | 55.32 |
| Average True Range | 3.47 |
| ADX | 31.82 |
| +DI | 22.72 |
| -DI | 16.57 |
| Chandelier Exit (Long, 3 ATRs) | 53.07 |
| Chandelier Exit (Short, 3 ATRs) | 61.35 |
| Upper Bollinger Bands | 64.06 |
| Lower Bollinger Band | 51.88 |
| Percent B (%b) | 0.17 |
| BandWidth | 21.01 |
| MACD Line | 1.60 |
| MACD Signal Line | 2.91 |
| MACD Histogram | -1.3101 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 60.41 | ||||
| Resistance 3 (R3) | 61.10 | 59.63 | 59.34 | ||
| Resistance 2 (R2) | 59.63 | 57.99 | 59.29 | 58.98 | |
| Resistance 1 (R1) | 56.80 | 56.98 | 56.07 | 56.11 | 58.62 |
| Pivot Point | 55.33 | 55.33 | 54.97 | 54.99 | 55.33 |
| Support 1 (S1) | 52.50 | 53.69 | 51.77 | 51.81 | 49.30 |
| Support 2 (S2) | 51.03 | 52.68 | 50.69 | 48.94 | |
| Support 3 (S3) | 48.20 | 51.03 | 48.59 | ||
| Support 4 (S4) | 47.51 |
